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Abstract. The sesquiterpene lactone parthenolide (PN) has 
recently attracted considerable attention because of its anti-
microbial, anti-inflammatory and anticancer effects. However, 
the mechanism of its cytotoxic action on tumor cells remains 
scarcely defined. We recently provided evidence that the effect 
exerted by PN in MDA-MB-231 breast cancer cells was medi-
ated by the production of reactive oxygen species (ROS). The 
present study shows that PN promoted the phosphorylation 
of EGF receptor (phospho-EGFR) at Tyr1173, an event which 
was observed already at 1 h of incubation with 25 µM PN and 
reached a peak at 8-16 h. This effect seemed to be a conse-
quence of ROS production, because N-acetylcysteine (NAC), a 
powerful ROS scavenger, prevented the increment of phospho-
EGFR levels. In addition fluorescence analyses performed 
using dihydroethidium demonstrated that PN stimulated the 
production of superoxide anion already at 2-3 h of incubation 
and the effect further increased prolonging the time of treat-
ment, reaching a peak at 8-16 h. Superoxide anion production 
was markedly hampered by apocynin, a well known NADPH 
oxidase (NOX) inhibitor, suggesting that the effect was depen-
dent on NOX activity. The finding that AG1478, an EGFR 
kinase inhibitor, substantially blocked both EGFR phosphory-
lation and superoxide anion production strongly suggested that 
phosphorylation of EGFR can be responsible for the activation 
of NOX with the consequent production of superoxide anion. 
Therefore, EGFR phosphorylation can exert a key role in the 
production of superoxide anion and ROS induced by PN in 
MDA-MB-231 cells.
Introduction
PN is a sesquiterpene lactone, derived from the medicinal plant 
feverfew Tanacetum parthenium, which is conventionally used 
to treat migraine and rheumatoid arthritis (1). In addition it 
has been shown that PN exhibits anticancer activity in several 
cancer cell types, such as colorectal cancer (2), pancreatic 
cancer (3), prostate cancer (4), multiple myeloma (5), osteosar-
coma and melanoma (6).
Recently we have demonstrated that PN exerted a marked 
cytotoxic effect on MDA-MB-231 cells, a triple-negative 
breast cancer cell line (7). This effect was not prevented by the 
caspase inhibitor z-VAD-fmk, while was counteracted by the 
ROS scavenger NAC. Cytotoxic action was primarily corre-
lated with generation of ROS, which in turn were responsible 
for induction of autophagy, dissipation of ∆ψm and necrotic 
events.
Epidermal growth factor receptor (EGFR), also known as 
human epidermal growth factor receptor (HER1 or erbB1), 
is a member of a family of tyrosine kinase receptors which 
includes three additional receptors: HER2 (erbB2), HER3 
(erbB3) and HER4 (erbB4) (8). In response to EGF binding, 
EGFR forms homo- or heterodimers with other HER family 
members, followed by autophosphorylation of key tyrosine 
residues located within the tyrosine kinase domain (8). Once 
activated, EGFR can promote proliferation and survival such 
as migration, invasion, differentiation, inhibition of apoptosis 
and angiogenesis (9-11).
EGFR and related family members have been found to be 
mutated or amplified in a number of human lung and breast 
cancers and this event has been associated with poor prog-
nosis, short survival and poor response to therapy (12,13).
Data from several research groups have shown that activa-
tion of EGFR can be involved in the production of ROS (14-16). 
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Moreover, it has been reported that endogenous hydrogen 
peroxide (H2O2), produced as a consequence of EGF binding 
to EGFR, can be utilized by the cells as a secondary messenger 
to regulate physiological signal transduction (17,18).
The aim of this study was to ascertain whether the 
activation of NADPH oxidase (NOX) induced by PN in 
MDA-MB-231 cells can be mediated by EGFR activation. The 
results demonstrate that treatment of MDA-MB-231 cells with 
PN increases the level of the phosphorylated form of EGFR 
(phospho-EGFR) and that this event is correlated with the 
activation of NOX and superoxide generation.
Materials and methods
Chemicals and reagents. All reagents were purchased from 
Sigma-Aldrich (Milan, Italy), except for recombinant human 
EGF (rhEGF), which was supplied from Clontech (Palo Alto, 
CA, USA) and AG1478, supplied from Calbiochem-Merk 
Millipore (Milan, Italy). PN, apocynin and AG1478 were 
solubilized in dimethyl sulfoxide (DMSO) and diluted to final 
concentration in the culture medium. Final concentration of 
DMSO employed as vehicle never exceeded 0.04% and had no 
discernible effects on MDA-MB-231 cells in comparison with 
the control.
Cell cultures. Human breast carcinoma cell line MDA-MB-231 
was provided by ‘Istituto Scientifico Tumori’ (Genoa, Italy). 
Cells were grown as monolayer in DMEM medium supple-
mented with 10% (v/v) heat inactivated fetal calf serum (FCS), 
2 mM glutamine and 1% non-essential amino acids, at 37˚C 
in a humidified atmosphere containing 5% CO2. After plating 
on 96- or 6-well plates, cells were allowed to adhere overnight 
and then treated with chemicals or vehicle only.
Western blot analysis. Whole cell lysates were prepared 
as previously reported (19) and protein concentration was 
determined by Lowry assay (20). Equal amounts of protein 
samples (50 µg/lane) were run in an SDS polyacrylamide gel 
electrophoresis, then transferred to a nitrocellulose membrane. 
Analyses of EGFR and phopho-EGFR were performed 
using specific antibodies which were provided by Santa 
Cruz Biotechnology (Santa Cruz, CA, USA). In particular, 
for phopho-EGFR an antibody recognizing phosphorylated 
Tyr1173 was used. Then the detection was developed by using 
a secondary antibody conjugated with alkaline phosphatase. 
Protein bands were visualized using nitroblue tetrazolium 
and 5-bromo-4-chloro-3-indoyl-phosphate and their intensity 
was quantified by densitometric analysis using SMX Image 
software. The correct protein loading was ascertained by red 
Ponceau staining and immunoblotting for β-actin. All the blots 
shown are representative of at least three separate experiments.
Measurement of superoxide production. The superoxide 
radical production was assessed by dihydroethidium (DHE) 
staining. DHE is a fluorochrome that is oxidized by super-
oxide to fluorescent ethidium that intercalates with nuclear 
DNA, staining the nucleus with a bright red fluorescence. 
MDA-MB-231 cells (8x103/well) were incubated with PN 
or other effectors, then cells were centrifuged at 120 x g 
for 5 min and culture medium was replaced with a solution 
of DHE (20 µM) in PBS. The incubation was protracted for 
10 min and DHE-positive cells were analysed by fluorescence 
microscopy using an excitation wavelength of 596 nm and an 
emission wavelength of 620 nm. All the images were acquired 
by Leica Q Fluoro Software. Percentage of DHE-positive cells 
was evaluated by using ImageJ software.
Statistical analysis. Results are presented as means ± standard 
error. Data were analysed using Student's t-test.
Results
PN stimulates EGFR phosphorylation. In the present study we 
evaluated whether the exposure of MDA-MB-231 cells to PN 
resulted in the phosphorylation and activation of EGFR and 
consequently in the induction of NOX activity.
It is well known that activation of EGFR depends on phos-
phorylation of the amino acid residue Tyr1173 (21). Therefore, 
MDA-MB-231 cells were treated with 25 µM PN for different 
times and subjected to western blot analysis to evaluate the 
level of phospho-EGFR by using an antibody recognizing 
phospho-Tyr1173. As shown in Fig. 1, the level of phospho-
EGFR was increased already at 1 h of treatment with PN. 
The effect was enhanced with time reaching the maximum 
at about 8 h of treatment, and remaining elevated up to 
16 h. Increment of EGFR phosphorylation was prevented by 
2 mM NAC, whatever the time of treatment was (Fig. 1), thus 
suggesting that the effect was a consequence of oxidative 
stress induction.
The effects of PN on MDA-MB-231 cells were compared 
with that exerted by recombinant human EGF (rhEGF), a 
direct EGFR ligand. Treatment of cells with 200 ng/ml rhEGF 
caused phosphorylation of EGFR with a maximum effect 
Figure 1. The effect of PN or rhEGF on EGFR phosphorylation. MDA-MB-231 
cells (2x105 cells/well) were treated for various times with 25 µM PN or 
200 ng/ml rhEGF without or with 2 mM NAC. At the end cell extracts were 
prepared and submitted to western blot analysis using a specific antibody 
recognizing EGFR phosphorylated on Tyr1173. The results are representative 
of three independent experiments.
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found between 1 and 3 h. Such an effect was much lower than 
that observed with PN and was only partially reduced by the 
addition of 2 mM NAC (Fig. 1). Finally treatment with rhEGF, 
in contrast with PN, did not exert any cytotoxic effect (not 
shown).
It is noteworthy that treatment of MDA-MB-231 cells 
with PN or rhEGF did not modify the level of the EGFR (not 
shown). Therefore, after PN or rhEGF treatment the amount 
of EGFR remained unchanged, whereas its tyrosine phos-
phorylation increased.
PN induces production of superoxide anion. ROS include 
superoxide anion (O2.-), which is a highly reactive oxygen 
species and hydrogen peroxide (H2O2). High doses of ROS, in 
particular superoxide anion, result in oxidative stress, which 
is implicated in the pathogenesis of a number of diseases and 
in the cytotoxic action of many drugs (22). NADPH oxidases 
(NOXs), which are present in phagocytes, but also in other 
somatic cells, are multicomponent enzymes that catalyze the 
generation of superoxide anion from oxygen and NADPH (23). 
NOX4 has been identified as the principal source of superoxide 
production in MDA-MB-231 cells (24).
In order to ascertain whether PN stimulated NOX activa-
tion in MDA-MB-231 cells, we evaluated the effect of the drug 
on superoxide production by using DHE, a specific fluorescent 
probe. It was observed that PN induced the appearance of 
intense red fluorescence, suggesting that the drug induced 
production of superoxide anion by stimulating NOX activity 
(Fig. 2). Such an effect was abrogated by either NAC or 
apocynin, a specific inhibitor of NOX activity (25).
Figure 2. Superoxide anion generation in PN- or rhEGF-treated cells. MDA-MB-231 cells (8x103/well) were treated for 8 h with 25 µM PN or for 3 h with 
200 ng/ml rhEGF, either in the presence or absence of 2 mM NAC or 100 µM apocynin or 20 µM AG1478. The plate was then centrifuged at 120 x g for 5 min 
and the culture medium replaced with 20 µM DHE in PBS. After 10 min of incubation, DHE-positive cells were analysed by fluorescence microscopy as 
described in Materials and methods. The results are representative of three independent experiments.
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A time course study showed that the production of super-
oxide anion increased already after 1 h of treatment with 
25 µM PN, reached the maximum at 8 h, when 72% of cells 
showed red fluorescence, and maintained a considerable level 
until 16 h (Fig. 3).
We also evaluated whether rhEGF treatment induced the 
production of superoxide anion. As shown in Fig. 2, the effect 
was observed particularly at 3 h of treatment and was lower 
than that found in PN-treated MDA-MB-231 cells.
Production of superoxide anion induced by PN is corre-
lated with EGFR activation. In order to ascertain a possible 
correlation between superoxide anion production and EGFR 
activation induced by PN treatment, we performed experi-
ments using AG1478, which is a specific inhibitor of the kinase 
activity of EGFR (26).
MDA-MB-231 cells were treated for 3 and 8 h with 25 µM 
PN in the presence or absence of 20 µM AG1478. In order 
to confirm the specificity of the inhibitory action exerted by 
AG1478, PN was substituted in some samples with 200 ng/ml 
rhEGF. Results reported in Fig. 4 show that the increase in the 
level of phospho-EGFR induced by both PN and rhEGF was 
prevented by AG1478. Then we evaluated the effect of AG1478 
on the production of superoxide anion in MDA-MB-231 cells 
stimulated with PN or rhEGF. Results shown in Fig. 2 demon-
strate that the addition of AG1478 to PN or rhEGF prevented, 
after incubation with DHE, the production of cells with red 
fluorescence. These results suggest that phosphorylation and 
activation of EGFR induced by PN were closely correlated 
with stimulation of NOX and production of superoxide anion.
Discussion
EGFR is a member of the ErbB family of tyrosine kinases, 
which is involved in the regulation of proliferation and differ-
entiation primarily of epithelial cell types (27). Following 
ligand binding, the EGFR dimerizes and the intracellular 
tyrosine kinase region is activated, causing receptor tyrosine 
autophosphorylation and transphosphorylation of another 
receptor monomer (27). These events lead to the recruitment 
and phosphorylation of several intracellular substrates and the 
subsequent transmission of extracellular signals to the nucleus 
via an intracellular signaling network (27).
EGFR activation plays important roles in the stimula-
tion of cell growth, survival, migration and differentiation 
(9,11). EGFR and related family members have been found 
to be mutated or amplified in a number of human lung and 
breast cancers (12,13,28,29). Our study was performed on 
MDA-MB-231 cells, a ‘triple-negative’ breast cancer cell line 
which lacks estrogen receptor α (ERα), progesterone receptor 
and HER2 (29). Instead MDA-MB-231 cells are known to 
contain high levels of EGFR (HER1) (29,30). This observa-
tion has been correlated with the absence in these cells of 
ERα, because an inverse relationship has been demonstrated 
between the presence of ERα and the level of EGFR (31).
In the present study we provide evidence that in 
MDA-MB-231 cells PN increased the level of the phosphory-
lated form of EGFR. This effect was remarkable between 8 and 
16 h of treatment. Furthermore, the production of phospho-
EGFR was prevented by NAC, a general ROS scavenger. Such 
a result suggests that PN effect was mediated by ROS genera-
tion. This conclusion agrees with our previous finding (7) that 
in MDA-MB-231 cells PN strongly induced production of 
ROS already in the first hours of treatment (1-3 h).
It has been shown also previously that a correlation exists 
between enhancement of ROS and phosphorylation of EGFR 
(32), and suggested that ROS could be responsible for the 
Figure 3. Time course evaluation of superoxide anion production. Cells 
(8x103/well) were treated with 25 µM PN or 200 ng/ml rhEGF for the indi-
cated times and superoxide anion was measured with DHE as reported in 
Materials and methods and in Fig. 2. Values are the means of three indepen-
dent experiments ± SE. *p<0.01 versus untreated control.
Figure 4. The effect of AG1478 or apocynin on EGFR phosphorylation. 
MDA-MB-231 cells (2x105 cells/well) were treated with 25 µM PN for 8 h or 
200 ng/ml rhEGF for 3 h either in the presence or absence of 20 µM AG1478 
or 100 µM apocynin. At the end, extracts were prepared and submitted to 
western blot analysis, using a specific antibody recognizing EGFR phos-
phorylated on Tyr1173 as described in Materials and methods. The results 
are representative of three independent experiments.
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reversible oxidization of thiol groups of the catalytic site of 
protein phosphatases, involved in dephosphorylation of EGFR 
(33,34). As a consequence phosphatases are inactivated and 
EGFR is maintained in the phosphorylated active form (34). 
However, other authors demonstrated that H2O2 directly 
can modify a specific cysteine residue (Cys797) of EGFR 
to sulfenic acid in the active site of the receptor, enhancing 
tyrosine kinase activity of EGFR (35).
Our results also show that PN increased the production 
of anion superoxide, reaching very high levels between 8 and 
16 h. The observation that the production of superoxide anion 
induced by PN was prevented by the addition of apocynin, 
an inhibitor of NOX, suggests the involvement of NOX in the 
production of superoxide.
Our study provides evidence that addition of AG1478, a 
specific inhibitor of EGFR tyrosine kinase, was capable of 
inhibiting the effects of PN both on EGFR phosphorylation 
and on the production of superoxide anion. Therefore it seems 
that phosphorylation of EGFR and activation of NOX are 
closely correlated. Such a correlation has been suggested by 
many other authors. In particular Tamàs et al (36) have shown 
that EGFR activates Rac1, a member of Rac GTPase involved 
in activation of the non-phagocytic NADPH oxidases (23), by 
phosphorylating and associating with Vav2 factor. Moreover, 
Sheng et al (37) reported that ofloxacin caused intracellular 
ROS production by activating EGFR-Rac1-NOX2 pathway.
Collectively, our results led us to the following conclu-
sions: PN generates already in the first phase of treatment 
(1-3 h) production of ROS; ROS activate phosphorylation of 
EGFR and this causes stimulation of NOX and new produc-
tion of ROS. These considerations suggest that the mechanism 
induced by PN is based on the creation of a positive feedback 
loop, which through the involvement of the EGFR sustains for 
a long period of time (16 h) activation of NOX and production 
of ROS.
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